$TAK

Platford Giles Richard sold $532K of TAK

Platford Giles Richard (President, IBU) sold 31,083 shares of TAKEDA PHARMACEUTICAL CO LTD (TAK) at $17.10 ($0.53M total) on 2026-08-10.

Original reporting
SEC EDGAR · Platford Giles Richard
Published Aug 13, 2026, 1:25 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 1:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TAK
Neutral
medium confidence
Mentioned
$TAK
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TAKNeutralLow
01

Why it matters

An officer (President, IBU) conducted an open-market sale of 31,083 shares at $17.10, totaling about $531.5k, with holdings after the trade of 315,838 shares.

02

Market read

Traders may note insider selling as a sentiment datapoint, but there is no accompanying fundamental or regulatory catalyst in the text.

03

What to watch

The article lacks context on total holdings, prior sale frequency, and whether other insiders or executives made offsetting purchases.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-12 for a sale dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for Takeda Pharmaceutical Co Ltd (TAK).

Company-level read

Ticker impact

$TAKNeutralMedium confidence
Context

Takeda’s Form 4 shows insider Platford Giles Richard sold 31,083 shares at $17.10 on 2026-08-10.

Expected impact

Likely limited near-term impact; treat as low-signal unless repeated or paired with other disclosures.

Evidence & confidence

The filing is primary-source and time-stamped, but insider sales alone typically have weak causal linkage to fundamentals, and the article provides no new operational or guidance catalyst.

Market effects

No sector read-through is provided beyond a single insider transaction at a large pharma company.

None indicated.

None indicated.

Counterpoint

The sale may be liquidity-driven (taxes, diversification) and the absence of a 10b5-1 plan does not necessarily imply negative expectations.

Key entities

  • TAK

    Takeda Pharmaceutical Co Ltd, the Form 4 issuer.

  • Platford Giles Richard

    President, IBU, who sold shares via open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TAKMedAI 9/10

Why Zasocitinib Outperformed Deucravacitinib in New Plaque Psoriasis Data

Zasocitinib, an investigational TYK2 inhibitor by Takeda, showed superior efficacy in treating plaque psoriasis compared to deucravacitinib in a phase 3 trial. 36.5% of patients achieved PASI 100 with zasocitinib vs. 13.9% with deucravacitinib. The drug's higher TYK2 selectivity and longer IL-23 blockade were cited as key factors. Zasocitinib is under review by the FDA and EMA.

$TAKHighAI 9/10

Oveporexton Improves Wakefulness and Cataplexy in Narcolepsy Type 1

Takeda's Oveporexton (Orzeyful) significantly improved wakefulness, daytime sleepiness, and cataplexy in narcolepsy type 1 patients over 12 weeks, according to two phase 3 trials. The FDA approved the drug in August 2026, positioning it as the first therapy addressing orexin deficiency. Adverse events included increased urinary frequency and transient insomnia. Trials showed mean sleep latency improvements of 14.3 to 19.8 minutes with Oveporexton vs. placebo.

$TAKMedAI 8/10

Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill

Takeda announced Phase 3 trial results showing zasocitinib (TAK-279) demonstrated superior efficacy in treating moderate-to-severe plaque psoriasis compared to deucravacitinib. Key data: 36.5% of patients achieved complete skin clearance (PASI 100) at week 16 vs. 13.9% for deucravacitinib. Zasocitinib also showed durable skin clearance and improvements in itch and quality of life. The drug is under regulatory review for psoriasis treatment.

$TAKMedAI 9/10

Takeda Pharmaceutical Company Limited: Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026

Takeda (TSE:4502/NYSE:TAK) will present data on its oncology pipeline at ESMO 2026, including Phase 3 results for arcotatug tavatecan in advanced gastric cancer and findings on TAK-928 for NSCLC. The company is expanding a global Phase 3 study for TAK-928.